HK Stock Market Move | LIFETECH SCI (01302) rises over 3%; the Yuranos Plus abdominal aortic stent graft system recently received NMPA approval for marketing

LIFETECH SCI (01302) rose over 3%, up 2.27% as of press time, at HK$1.35, with a turnover of HK$19.5463 million. On the news front, recently, according to LIFETECH SCI's official WeChat account, the company's independently developed Yuranos Plus abdominal aortic stent graft system (Yuranos Plus) has received registration approval from the National Medical Products Administration (NMPA) and officially entered the Chinese market. Yuranos Plus is a comprehensive upgrade based on the Yuranos abdominal aortic stent graft system, indicated for endovascular treatment of infrarenal abdominal aortic aneurysms, particularly providing a superior minimally invasive interventional solution for patients with complex aneurysm neck anatomy and narrow, tortuous access vessels.